Sargent Investment Group, LLC Taysha Gene Therapies, Inc. Transaction History

Sargent Investment Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$0.59 - $0.87 $3,578 - $5,276	6,065 Added 30.99%	25,634 $16,000
Q1 2023 May 02, 2023	SELL	$0.65 - $2.3 $15,221 - $53,861	-23,418 Reduced 54.48%	19,569 $15,000
Q4 2022 Jan 31, 2023	BUY	$1.39 - $2.98 $24,665 - $52,880	17,745 Added 70.3%	42,987 $97,000
Q3 2022 Oct 26, 2022	BUY	$1.76 - $4.94 $13,119 - $36,822	7,454 Added 41.9%	25,242 $47,000
Q2 2022 Jul 26, 2022	BUY	$2.47 - $6.77 $17,616 - $48,283	7,132 Added 66.93%	17,788 $66,000
Q1 2022 May 06, 2022	BUY	$5.22 - $11.86 $55,624 - $126,380	10,656 New	10,656 $69,000

117

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $85.1M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Sargent Investment Group, LLC with notifications on news.